{"filing":{"accession_number":"0001213900-26-064744","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"ea0293458-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/ea0293458-8k_cadrenal.htm"},"events":[{"id":3145,"run_id":2740,"accession_number":"0001213900-26-064744","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Matthew K. Szot departed as Chief Financial Officer effective May 28, 2026, following a mutual agreement with the Company. While the filing also discloses the interim appointment of Quang X. Pham as interim CFO and severance arrangements totaling approximately $603,709 in cash and accelerated equity vesting, the principal disclosed action centers on Szot's departure. The departure of a CFO is material to investors assessing financial reporting oversight and continuity.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-03","items":[{"id":4028,"accession_number":"0001213900-26-064744","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Matthew K. Szot departed as Chief Financial Officer effective May 28, 2026, following a mutual agreement with the Company. While the filing also discloses the interim appointment of Quang X. Pham as interim CFO and severance arrangements totaling approximately $603,709 in cash and accelerated equity vesting, the principal disclosed action centers on Szot's departure. The departure of a CFO is material to investors assessing financial reporting oversight and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:33.028621+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4028,"accession_number":"0001213900-26-064744","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Matthew K. Szot departed as Chief Financial Officer effective May 28, 2026, following a mutual agreement with the Company. While the filing also discloses the interim appointment of Quang X. Pham as interim CFO and severance arrangements totaling approximately $603,709 in cash and accelerated equity vesting, the principal disclosed action centers on Szot's departure. The departure of a CFO is material to investors assessing financial reporting oversight and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:33.028621+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-03"}]}